Farmas USA

Hola Mugiwara. Vas a entrar?

En PBYI? No tenía pensado no. Igual en ADXS buscando un rebote intradía y TGTX en los 9,55$ si se da durante la semana. Eso son mis 2 únicos objetivos por ahora.

USA esta despertando, futuro rojos, sesiones europeas del verde al rojo ...

CLSN

Presents Data from Ongoing ThermoDox Combo Phase 1/2; LRR Seen at 61.9%

http://www.streetinsider.com/Corporate+News/Celsion+%28CLSN%29+Presents+Data+from+Ongoing+ThermoDox+Combo+Phase+12%3B+LRR+Seen+at+61.9%25/11149801.html?si_client=intbro

Celsion Announces Presentation of DIGNITY Phase I/II ThermoDox® Data at the 2015 San Antonio Breast Cancer Symposium

In the Phase I/II trials, which were designed to evaluate the safety and anti-tumor activity of ThermoDox® in combination with mild hyperthermia in RCW breast cancer, a total of 28 patients were treated at doses of either 40 or 50 mg/m2. In addition to a local response rate of 61.9% among evaluable patients, a combined local response rate was observed in 46.4% of the intent-to-treat population (13/28), notably consisting of five patients demonstrating a durable local response lasting greater than three months, including four complete responses (CR) and one partial response (PR). Patients dosed at 40 mg/m2 displayed a comparable response rate and a more favorable safety profile to that of patients receiving 50 mg/m2. As a result, 40 mg/m2 will be the recommended dose for future clinical trials in this indication.

The Company anticipates completion of the Phase II US DIGNITY trial by year-end, and plans to initiate a 70 patient Phase II study in Europe and Israel in less advanced, less heavily pretreated patients as part of the Euro-DIGNITY Trial. The Euro-DIGNITY Trial will evaluate ThermoDox® plus radiation and hyperthermia in RCW breast cancer patients and is designed to support a registration filing in Europe. This study will be initiated throughout Europe and Israel and with assistance from MedLogics Corporation, an Italian-based hyperthermia device company. In addition, Celsion has a license and distribution agreement with myTomorrows to implement an Early Access Program (EAP) for ThermoDox® in all countries of the European Union territory plus Switzerland for the treatment of patients with RCW breast cancer.
http://investor.celsion.com/releaseDetail.cfm?ReleaseID=946821

ONTY

One of the highlighted studies focused on the use of, ONT-380 (Oncothyreon), which has demonstrated clinical benefit for HER-2 positive breast cancer patients with brain metastases.

Approximately 20 percent of breast cancers overexpress HER-2, a more aggressive subtype. Therapies that target HER-2 with either antibodies or small molecules have been shown to improve both progression free and overall survival. Despite these improvements, up to a quarter of all patients treated with anti-HER-2 therapy in the adjuvant setting eventually relapse and most patients with metastatic breast cancer will eventually experience disease progression.

“One of the challenges in treating HER-2 positive breast cancer is the frequent development of brain metastases, which occur in up to 50 percent of patients with advanced disease. Most available therapies for this type of breast cancer do not cross into the brain well, and we desperately need new treatments to help this patient population,” said Hamilton. “We have observed that ONT-380 is showing promising early results in clinical trials, when used in combination with other standard medications, to safely treat HER-2 cancers in the brain and also in other areas of the body.”

http://www.businesswire.com/news/home/20151211005958/en/Sarah-Cannon-Highlights-Latest-Data-Targeted-Therapies

IDRA

Begins Enrollment in IMO-2125 Combo Phase 1/2

trial evaluating intra-tumoral IMO-2125, a TLR9 agonist in combination with ipilimumab (an anti-CTLA4 antibody) in patients with previously treated metastatic melanoma.

http://www.streetinsider.com/Corporate+News/Idera+Pharma+%28IDRA%29+Begins+Enrollment+in+IMO-2125+Combo+Phase+12/11149751.html?si_client=intbro

ADXS

Advaxis Receives Orphan Drug Designation in the European Union for Axalimogene Filolisbac for the Treatment of Anal Cancer

http://finance.yahoo.com/news/advaxis-receives-orphan-drug-designation-140500349.html

OK.

ADXS

Orphan Drug Designation In EU For Axalimogene Filolisbac For Treatment Of Anal Cancer (Healthcare)

Buena noticia!!!!